Cargando…

9-ING-41, a small molecule inhibitor of GSK-3beta, potentiates the effects of anticancer therapeutics in bladder cancer

Glycogen synthase kinase-3 beta (GSK-3β), a serine/threonine kinase, has been identified as a potential therapeutic target in human bladder cancer. In the present study, we investigated the antitumor effect of a small molecule GSK-3β inhibitor, 9-ING-41, currently in clinical studies in patients wit...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kuroki, Hiroo, Anraku, Tsutomu, Kazama, Akira, Bilim, Vladimir, Tasaki, Masayuki, Schmitt, Daniel, Mazar, Andrew P., Giles, Francis J, Ugolkov, Andrey, Tomita, Yoshihiko
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6934761/ https://www.ncbi.nlm.nih.gov/pubmed/31882719 http://dx.doi.org/10.1038/s41598-019-56461-4

Ejemplares similares

Clinically relevant GSK-3β inhibitor 9-ING-41 is active as a single agent and in combination with other antitumor therapies in human renal cancer
por: Anraku, Tsutomu, et al.
Publicado: (2020)

Development of patient-derived tumor organoids and a drug testing model for renal cell carcinoma
por: Kazama, Akira, et al.
Publicado: (2021)

Targeting Pro-Survival Autophagy Enhanced GSK-3β Inhibition-Induced Apoptosis and Retarded Proliferation in Bladder Cancer Cells
por: Shirono, Yuko, et al.
Publicado: (2023)

Tumor-infiltrating immune cell status predicts successful response to immune checkpoint inhibitors in renal cell carcinoma
por: Kazama, Akira, et al.
Publicado: (2022)

Histone deacetylase 6 inhibition in urothelial cancer as a potential new strategy for cancer treatment
por: Kuroki, Hiroo, et al.
Publicado: (2021)

GSK-3β inhibitor, 9-ING-41, reduces cell viability and halts proliferation of B-cell lymphoma cell lines as a single agent and in combination with novel agents
por: Karmali, Reem, et al.
Publicado: (2017)

Combination Treatment with the GSK-3 Inhibitor 9-ING-41 and CCNU Cures Orthotopic Chemoresistant Glioblastoma in Patient-Derived Xenograft Models()()
por: Ugolkov, Andrey, et al.
Publicado: (2017)

MicroRNAs as Potential Regulators of GSK-3β in Renal Cell Carcinoma
por: Murata, Masaki, et al.
Publicado: (2023)

9-ING-41, a Small Molecule Inhibitor of GSK-3β, Potentiates the Effects of Chemotherapy on Colorectal Cancer Cells
por: Poloznikov, Andrey, et al.
Publicado: (2021)

Advanced Bladder Cancer: Changing the Treatment Landscape
por: Bilim, Vladimir, et al.
Publicado: (2022)

Clinical activity of 9-ING-41, a small molecule selective glycogen synthase kinase-3 beta (GSK-3β) inhibitor, in refractory adult T-Cell leukemia/lymphoma
por: Hsu, Andrew, et al.
Publicado: (2022)

GSK-3β in Pancreatic Cancer: Spotlight on 9-ING-41, Its Therapeutic Potential and Immune Modulatory Properties
por: Park, Robin, et al.
Publicado: (2021)

Elraglusib (formerly 9-ING-41) possesses potent anti-lymphoma properties which cannot be attributed to GSK3 inhibition
por: Coats, Josh T., et al.
Publicado: (2023)

Glycogen Synthase Kinase-3β Inhibition with 9-ING-41 Attenuates the Progression of Pulmonary Fibrosis
por: Jeffers, Ann, et al.
Publicado: (2019)

Malignant glioma subset from actuate 1801: Phase I/II study of 9-ING-41, GSK-3β inhibitor, monotherapy or combined with chemotherapy for refractory malignancies
por: Odia, Yazmin, et al.
Publicado: (2022)

GSK-3 directly regulates phospho-4EBP1 in renal cell carcinoma cell-line: an intrinsic subcellular mechanism for resistance to mTORC1 inhibition
por: Ito, Hiromi, et al.
Publicado: (2016)

Corepressive function of nuclear receptor coactivator 2 in androgen receptor of prostate cancer cells treated with antiandrogen
por: Takeda, Keisuke, et al.
Publicado: (2016)

Limited significance of repeated long-term radiological and hormonal examination in nonfunctioning adrenal incidentalomas
por: Tasaki, Masayuki, et al.
Publicado: (2019)

Aberrant expression of glycogen synthase kinase-3β in human breast and head and neck cancer
por: Ugolkov, Andrey V., et al.
Publicado: (2018)

Congenital Scaphoid Megalourethra: A Case Report
por: Obara, Kenji, et al.
Publicado: (2017)

Emergence of beta/gamma oscillations: ING, PING, and what about RING?
por: Moca, Vasile V, et al.
Publicado: (2011)

Elraglusib (9-ING-41), a selective small-molecule inhibitor of glycogen synthase kinase-3 beta, reduces expression of immune checkpoint molecules PD-1, TIGIT and LAG-3 and enhances CD8(+) T cell cytolytic killing of melanoma cells
por: Shaw, Gary, et al.
Publicado: (2022)

Archibald Inglis
Publicado: (1889)

Mallet-ing
Publicado: (1860)

Inge Borghuis
por: Kiers, Bart
Publicado: (2020)

Virilization of a female infant genitalia caused by a maternal androgen-producing adrenocortical tumor: A case report
por: Hoshino, Sayaka, et al.
Publicado: (2020)

A Case of Myxoid Adrenocortical Neoplasm: Computed Tomography and Magnetic Resonance Imaging Characteristics
por: Fukuhara, Hiroki, et al.
Publicado: (2013)

Inge J. Lissajoux
Publicado: (2016)

Orbit(ing) the furrow
por: Sreenivasan, Aparna
Publicado: (2004)

SNP'ing for longevity
por: Vijg, Jan
Publicado: (2009)

Check'-ing DLBCL
por: Salaverria, Itziar, et al.
Publicado: (2015)

Elsie Maud Inglis
por: Russell, Beatrice
Publicado: (1918)

David Wood Inglis
Publicado: (1934)

Professor Inglis of Aberdeen
Publicado: (1875)

GSK3-beta as a candidate therapeutic target in soft tissue sarcomas
por: Verbeke, S., et al.
Publicado: (2021)

Activity of the integrase inhibitor S/GSK1349572 in subjects with HIV exhibiting raltegravir resistance: week 24 results of the VIKING study (ING112961)
por: Eron, J, et al.
Publicado: (2010)

FRET-ing over scaffolds
por: LeBrasseur, Nicole
Publicado: (2003)

Gett(er)ing to nothing
por: Benvenuti, Cristoforo
Publicado: (2004)

Spy'ing on differentiation in neuroblastoma
por: Podkowa, Monika, et al.
Publicado: (2014)

STIR(ing) appearance of rhabdomyolysis
por: Chakera, Aron, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_epck72vfvb19mo483n5su3mh5n